Anmelden
DieBuchSuche.ch - Bücher einfach finden - SchweizDie Buch Suche - Versandkosten nach: Schweiz
Buchsuche - SchweizAlle lieferbaren Bücher und Raritäten.

Von dem Buch ACE Inhibitors (Milestones in Drug Therapy) haben wir 2 gleiche oder sehr ähnliche Ausgaben identifiziert!

Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:

Ähnliche Ausgaben haben zumindest bei Autor und Titel eine Übereinstimmung.

ACE Inhibitors (Milestones in Drug Therapy) - alle Angebote vergleichen

Preise201320142015
SchnittFr. 97.32 ( 90.85)¹ Fr. 99.67 ( 93.05)¹ Fr. 107.18 ( 100.06)¹
Nachfrage
9783034875790 - Birkhauser: ACE Inhibitors
1
Birkhauser (?):

ACE Inhibitors (2012) (?)

Lieferung erfolgt aus/von: Niederlande

ISBN: 9783034875790 (?) bzw. 3034875797, in Deutsch, Birkhauser, neu

Fr. 77.10 ( 71.98)¹ + Versand: Fr. 3.70 ( 3.45)¹ = Fr. 80.80 ( 75.43)¹(unverbindlich)
Direct beschikbaar
bol.com
Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis- order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun- tries [1]. CAPTOPRIL, the prototype of the PRIL family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop- ment almost failed when serious side-effects were reported in an alarmist fash- ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the PRIL family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar- macological actions. Inhoud:Taal: Engelstalig;EAN: 9783034875790;Bindwijze: E-book;Verschijningsdatum: 2012-12-06; Engelstalig | E-book | 2001 | 9783034875790
2

ACE Inhibitors (Paperback) (2012) (?)

ISBN: 9783034875813 (?) bzw. 3034875819, in Deutsch, Springer Basel, Switzerland, Taschenbuch, neu, Nachdruck

Fr. 100.79 ( 94.09)¹ + Versand: Fr. 1.46 ( 1.36)¹ = Fr. 102.25 ( 95.45)¹(unverbindlich)
Von Händler/Antiquariat, The Book Depository EURO [60485773], London, United Kingdom
Language: English Brand New Book ***** Print on Demand *****.Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis- order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun- tries [1]. CAPTOPRIL, the prototype of the PRIL family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop- ment almost failed when serious side-effects were reported in an alarmist fash- ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the PRIL family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar- macological actions. Softcover reprint of the original 1st ed. 2001.
3
Herausgegeben von D'Orléans-Juste, Pedro Plante, G.E. (?):

ACE Inhibitors (?)

ISBN: 9783034875813 (?) bzw. 3034875819, in Deutsch, Birkhäuser, Taschenbuch, neu

Fr. 77.07 ( 71.95)¹(versandkostenfrei, unverbindlich)
Versandkostenfrei
buecher.de GmbH & Co. KG, [1]
Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions.2012. x, 187 S. 24 SW-Abb.,Versandfertig in 3-5 Tagen, Softcover
9783034875790 - G.E. Plante, Pedro D'Orléans-Juste: ACE Inhibitors
4
G.E. Plante, Pedro D'Orléans-Juste (?):

ACE Inhibitors (2012) (?)

ISBN: 9783034875790 (?) bzw. 3034875797, in Deutsch, Birkhäuser, Birkhäuser, Birkhäuser, neu, E-Book, elektronischer Download

Fr. 68.96 ($ 80.09)¹(versandkostenfrei, unverbindlich)
in-stock
Von Händler/Antiquariat
Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis- order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun- tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop- ment almost failed when serious side-effects were reported in an alarmist fash- ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B, ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar- macological actions.
9783034875790 - Pedro D'Orléans-Juste; G.E. Plante: ACE Inhibitors
5
Pedro D'Orléans-Juste; G.E. Plante (?):

ACE Inhibitors (?)

ISBN: 9783034875790 (?) bzw. 3034875797, in Deutsch, Springer Nature, neu, E-Book

Fr. 72.65 ( 67.82)¹(unverbindlich)
Lagernd, zzgl. Versandkosten
Von Händler/Antiquariat
diseases, enzymes, genetics, health policy, heart, metabolism, nervous system, pharmacodynamics, research, therapy, tissue, Medicine & Public Health; Medicine/Public Health, general, eBook
6
D'Orleans-Juste, Pedro and Plante, G. E. (?):

Ace Inhibitors (2015) (?)

ISBN: 9783034875813 (?) bzw. 3034875819, in Deutsch, SPRINGER VERLAG GMBH 01/08/2015, Taschenbuch, neu

Fr. 92.16 ( 86.03)¹ + Versand: Fr. 13.27 ( 12.39)¹ = Fr. 105.43 ( 98.42)¹(unverbindlich)
Von Händler/Antiquariat, Books2Anywhere [190245], Fairford, GLOS, United Kingdom
New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. This item is printed on demand.
7

ACE Inhibitors (Milestones in Drug Therapy) (2012) (?)

ISBN: 9783034875813 (?) bzw. 3034875819, in Deutsch, Birkhäuser, Taschenbuch, neu, Nachdruck

Fr. 98.23 ( 91.70)¹ + Versand: Fr. 3.21 ( 3.00)¹ = Fr. 101.44 ( 94.70)¹(unverbindlich)
Von Händler/Antiquariat, English-Book-Service Mannheim [1048135], Mannheim, Germany
This item is printed on demand for shipment within 3 working days.
8

ACE Inhibitors (Milestones in Drug Therapy) (2012) (?)

ISBN: 9783034875813 (?) bzw. 3034875819, in Deutsch, Birkhaeuser, Taschenbuch, neu

Fr. 202.35 ( 188.90)¹ + Versand: Fr. 8.85 ( 8.26)¹ = Fr. 211.20 ( 197.16)¹(unverbindlich)
Von Händler/Antiquariat, Revaluation Books [2134736], Exeter, United Kingdom
reprint edition. In Stock.
9783034875790 - Thomas Kreis: ACE Inhibitors
9
Thomas Kreis (?):

ACE Inhibitors (?)

ISBN: 9783034875790 (?) bzw. 3034875797, in Deutsch, Wiley, neu, E-Book, elektronischer Download

Fr. 74.02 (£ 61.20)¹ + Versand: Fr. 12.08 (£ 9.99)¹ = Fr. 86.10 (£ 71.19)¹(unverbindlich)
Despatched same working day before 3pm
Von Händler/Antiquariat